MDGL
Madrigal Pharmaceuticals IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$11.74B
P/E Ratio
—
EPS
$-12.85
Beta
-1.01
52W High
$615.00
52W Low
$265.00
50-Day MA
$467.49
200-Day MA
$448.18
Dividend Yield
—
Profit Margin
-30.10%
Forward P/E
666.67
PEG Ratio
0.00
About Madrigal Pharmaceuticals Inc
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic and liver diseases. The company is headquartered in West Conshohocken, Pennsylvania.
Fundamentals
| Revenue (TTM) | $958.40M |
| Gross Profit (TTM) | $902.25M |
| EBITDA | $-298.59M |
| Operating Margin | -18.60% |
| Return on Equity | -42.50% |
| Return on Assets | -16.30% |
| Revenue/Share (TTM) | $42.72 |
| Book Value | $26.39 |
| Price-to-Book | 20.82 |
| Price-to-Sales (TTM) | 12.25 |
| EV/Revenue | 12.43 |
| EV/EBITDA | -8.32 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 210.80% |
| Shares Outstanding | $22.94M |
| Float | $12.49M |
| % Insiders | 7.71% |
| % Institutions | 104.65% |
Analyst Ratings
Consensus ($668.57 target)
3
Strong Buy11
Buy2
HoldData last updated: 4/8/2026